Comparative Pharmacology
Head-to-head clinical analysis: SODIUM IODIDE I 123 versus YTTERBIUM YB 169 DTPA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SODIUM IODIDE I 123 versus YTTERBIUM YB 169 DTPA.
SODIUM IODIDE I 123 vs YTTERBIUM YB 169 DTPA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sodium iodide I 123 is a radioactive isotope that emits gamma radiation. Following oral or intravenous administration, it is rapidly absorbed and selectively concentrated in the thyroid gland via the sodium-iodide symporter (NIS). The emitted gamma rays allow for imaging of thyroid tissue and detection of abnormal uptake patterns.
Ytterbium Yb 169 DTPA is a radiopharmaceutical that emits gamma radiation. After administration, it distributes in the extracellular fluid and is cleared by glomerular filtration. Its mechanism of action is based on physical decay emission of photons for imaging, with no pharmacological effect.
Oral: 400-800 μCi (14.8-29.6 MBq) for thyroid uptake studies; 150-300 μCi (5.6-11.1 MBq) for thyroid scan. Administer orally as a single dose.
No standard therapeutic dosing; used as a diagnostic radiopharmaceutical. Typical adult activity: 37-111 MBq (1-3 mCi) intravenous injection for cisternography or CSF shunt evaluation.
None Documented
None Documented
13.2 hours (physical T1/2); effective T1/2 ~13 hours in euthyroid; prolonged in hypothyroidism.
Terminal: 25-50 days (effective half-life due to physical decay of Yb-169); clinical context: imaging agent for cisternography, half-life reflects biological clearance with physical decay (T1/2 physical: 32 days)
Primarily renal (90%) as iodide; small amount feces (<5%) and negligible biliary.
Renal: >90% unchanged; biliary/fecal: <10%
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical